The Prognostic Value of Blood Count Parameters in Patients with Diffuse Large B Cell Lymphoma

Cilt: 7 Sayı: 1 1 Ocak 2021
  • Hacer Berna Afacan Öztürk
  • Murat Albayrak
  • Abdulkerim Yıldız
  • Senem Maral
  • Pınar Cömert
  • Buğra Sağlam
  • Mesut Tığlıoğlu
PDF İndir
TR EN

The Prognostic Value of Blood Count Parameters in Patients with Diffuse Large B Cell Lymphoma

Abstract

Objective: Full blood count with the associated components is a widely used marker in the diagnosis of patients with diffuse large B cell lymphoma DLBCL as it is simple and inexpensive and can be easily interpreted. The aim of the current study was to evaluate the prognostic role of complete blood count parameters with the associated components in patients with DLBCL.Material and Methods: In this retrospective study, the neutrophil/lymphocyte ratio NLR , lymphocyte/monocyte ratio LMR , and platelet/lymphocyte ratio PLR were evaluated and an analysis was made of the progression-free survival PFS and overall survival OS in patients who were diagnosed with DLBCL and treated with a total of 6 cycles of R-CHOP chemotherapy in the 2011-2017 period.Results: 66 patients were included in the study. In the Cox-Regression Model, high NLR and the low LMR were associated with short OS and PFS; high PLR was associated with short PSF.Conclusion: Pre-treatment NLR, LMR, and PLR values can be used as prognostic factors in DLBCL patients

Keywords

Kaynakça

  1. Cultrera JL, Dalia SM. Diffuse large B-cell lymphoma: Current strategies and future directions. Cancer Control 2012; 19(3):204-13.
  2. Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2011; 498-505.
  3. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, André M, Johnson PW, Pfreundschuh M, Ladetto M. ESMO Guidelines Committee. Diffuse Large B-cell Lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 5:116-25.
  4. Bizjak M, Selmi C, Praprotnik S, Bruck O, Perricone C, Ehrenfeld M, Shoenfeld Y. Silicone implants and lymphoma: The role of inflammation. J Autoimmun 2015; 65:64-73.
  5. Baecklund E, Smedby KE, Sutton LA, Askling J, Rosenquist R. Lymphoma development in patients with autoimmune and inflammatory disorders-what are the driving forces? Semin Cancer Biol 2014; 24:61-70.
  6. Li ZM, Huang JJ, Xia Y, Sun J, Huang Y, Wang Y, Zhu YJ, Li YJ, Zhao W, Wei WX, Lin TY, Huang HQ, Jiang WQ. Blood lymphocyte-to-monocyte ratio identifies high- risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One 2012; 7(7):e41658.
  7. Aoki K, Tabata S, Yonetani N, Matsushita A, Ishikawa T. The prognostic impact of absolute lymphocyte and monocyte counts at diagnosis of diffuse large B-cell lymphoma in the rituximab era. Acta Haematol 2013; 130:242-6.
  8. Koh YW, Park CS, Yoon DH, Suh C and Huh J. Should the cut-off values of the lymphocyte to monocyte ratio for prediction of prognosis in diffuse large B-cell lymphoma be changed in elderly patients? Eur J Haematol 2014; 93:340-8.

Ayrıntılar

Birincil Dil

İngilizce

Konular

-

Bölüm

-

Yazarlar

Hacer Berna Afacan Öztürk Bu kişi benim

Murat Albayrak Bu kişi benim

Abdulkerim Yıldız Bu kişi benim

Senem Maral Bu kişi benim

Pınar Cömert Bu kişi benim

Buğra Sağlam Bu kişi benim

Mesut Tığlıoğlu Bu kişi benim

Yayımlanma Tarihi

1 Ocak 2021

Gönderilme Tarihi

-

Kabul Tarihi

-

Yayımlandığı Sayı

Yıl 2021 Cilt: 7 Sayı: 1

Kaynak Göster

Vancouver
1.Hacer Berna Afacan Öztürk, Murat Albayrak, Abdulkerim Yıldız, Senem Maral, Pınar Cömert, Buğra Sağlam, Mesut Tığlıoğlu. The Prognostic Value of Blood Count Parameters in Patients with Diffuse Large B Cell Lymphoma. Akd Tıp D [Internet]. 01 Ocak 2021;7(1):65-70. Erişim adresi: https://izlik.org/JA63PU49JL